The EPS projection of Quest Diagnostics Incorporated (NYSE:DGX) for quarter ended 2016-09-30 is $1.37. Last week, the projection for EPS was $1.37 against target of $1.37, a month earlier. While 2-months ago, this projection was $1.37 versus forecast of $1.37a quarter months earlier, posting a deviation of 0%.
Quest Diagnostics Incorporated (NYSE:DGX) posted that 18 days earlier, the share price was revised 5 times on upside. In addition, negative revisions were 3.
In last week, negative EPS revisions were 0 times and positive EPS revisions were 0 times. In last one-month and two month the positive revisions were 1 and 4. While in last 120 and 90 days, positive revisions were 2, and 2, correspondingly.
The per-share earnings downgrade for Quest Diagnostics Incorporated (NYSE:DGX) in the preceding 30 and 120 were 0 and 7. While in 60 and 90 days were 0, and 7, in that order.
Quest Diagnostics Incorporated (NYSE:DGX) EPS target was $1.37 for the quarter closed 1. It was based on 11 calls. As on 2016-04-21 the EPS was $1.12. The change was $0, posting a deviation of 0%. The price projections gave a standard deviation of 0.02.
Quarterly Sales Estimates
Quest Diagnostics Incorporated (NYSE:DGX) sales prediction for the fiscal 2017 stands at $1905.2 and the median estimate is at $1898.6. Almost 3 analysts gave sales target.
Among this, the highest sales estimate is $1926 while the lowest target is $1891 showing standard deviation of 18.409%.
As many as 3 analysts have positive sales targets revision while 3 reduced sales estimates, posting a deviation of 0%.
Last month, 3 experts have positive sales number revision. Also, 3 research groups lowered the sales projections, posting a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast, posting a deviation of -0.777%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...